Auris Medical Holding Financials

Auris Medical Stock Summary

Auris Medical competes with Transphorm Technology, Jeld Wen, National Beverage, Apogee Enterprises, and Keurig Dr. Auris Medical Holding Ltd., a clinical-stage biopharmaceutical company, developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy, and CNS disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Hamilton, Bermuda. Auris Medical operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people.

Auris Medical Key Financial Ratios

Generally speaking, Auris Medical's financial ratios allow both analysts and investors to convert raw data from Auris Medical's financial statements into concise, actionable information that can be used to evaluate the performance of Auris Medical over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Auris Medical Holding reports annually and quarterly.

Auris Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Auris Medical's current stock value. Our valuation model uses many indicators to compare Auris Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Auris Medical competition to find correlations between indicators driving Auris Medical's intrinsic value. More Info.Auris Medical Holding is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Auris Medical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Auris Medical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Auris Medical's earnings, one of the primary drivers of an investment's value.

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

If you are still planning to invest in Auris Medical Holding check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Auris Medical's history and understand the potential risks before investing.